Lifecore Biomedical (LFCR) Q2 2024 earnings summary

Executive summary

• Transitioned to a pure-play CDMO, exiting all food-related businesses as of May 28, 2023, focusing on sterile injectable pharmaceuticals and HA manufacturing.

• Operates as a single reportable segment, leveraging 40+ years of expertise in HA-based and aseptic manufacturing.

Financial highlights

• Total revenues for Q2 FY2024 were $30.2M, up 38% year-over-year; gross profit rose 75% to $10.0M.

• Net income for the quarter was $14.2M, compared to a net loss of $12.8M in the prior year.

• Adjusted EBITDA for the quarter was $5.4M, compared to $1.5M in the prior year.

• Gross margin improved to 33.0% from 26.0% year-over-year.

• Cash at quarter-end was $3.2M, down from $19.1M at fiscal year-end.

Outlook and guidance

• Management expects cash from operations, existing cash, and credit facility availability to be sufficient for at least the next twelve months.

• Strategic capital investments continue to support growth in aseptic filling and HA manufacturing.